New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 8, 2014
ARM Holdings (ARMH) upgraded to Market Perform from Underperform at Bernstein... Allegiant Travel (ALGT) upgraded to Buy from Hold at Deutsche Bank... Eli Lilly (LLY) upgraded to Market Perform from Underperform at BMO Capital... Estee Lauder (EL) upgraded to Outperform from Market Perform at Bernstein... Harman (HAR) upgraded to Strong Buy from Outperform at Raymond James...Hub Group (HUBG) upgraded to Buy from Hold at BB&T... Mallinckrodt (MNK) upgraded to Outperform from Market Perform at BMO Capital... Nike (NKE) upgraded to Buy from Hold at Stifel... S Ecology (ECOL) upgraded to Buy from Hold at KeyBanc... WABCO (WBC) upgraded to Conviction Buy from Buy at Goldman... Yelp (YELP) upgraded to Buy from Neutral at SunTrust... (WWWW) upgraded to Buy from Hold at Craig-Hallum... FireEye (FEYE) upgraded at Wedbush... Synageva (GEVA) upgraded at Wedbush... Vipshop (VIPS) upgraded to Outperform from Neutral at Credit Suisse... North American Palladium (PAL) upgraded to Sector Performer at CIBC... CACI International (CACI) upgraded to Outperform from Underperform at Raymond James... ON Semiconductor (ONNN) upgraded to Buy from Neutral at MKM Partners... Laclede (LG) upgraded to Buy from Hold at Stifel.
Check below for free stories on ARMH;ALGT;LLY;EL;HAR;HUBG;MNK;NKE;WBC;YELP;WWWW;FEYE;GEVA;VIPS;PAL;CACI;ONNN;LG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
September 10, 2014
10:00 EDTHUBGOn The Fly: Analyst Initiation Summary
Subscribe for More Information
10:00 EDTONNN, HUBGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:32 EDTHUBGHub Group downgraded to Market Perform from Strong Buy at Raymond James
Subscribe for More Information
07:04 EDTLLYEU grants marketing authorization for Eli Lilly's insulin glargine product
The European Commission granted marketing authorization for Eli Lilly and Boehringer Ingelheim's insulin glargine product, indicated to treat diabetes in adults, adolescents and children aged 2 years and above. Lilly/Boehringer Ingelheim's insulin glargine product is the first insulin treatment approved through the European Medicines Agency's biosimilar pathway and the fourth diabetes product approved in the EU from the Lilly-Boehringer Ingelheim alliance. It received a positive recommendation from the Committee for Medicinal Products for Human Use on June 26. The marketing authorisation for the alliance's insulin glargine product is based upon a comprehensive clinical data program. The application included results from pharmacokinetic and pharmacodynamic studies, as well as Phase III studies in patients with type 1 and type 2 diabetes.
06:33 EDTONNNON Semiconductor downgraded to Neutral from Outperform at RW Baird
Baird downgraded On Semiconductor to Neutral to reflect expectations for a Q4 slowdown in notebooks, TD-LTE smartphones, and servers and now sees indications where MOSFET and MCU lead times are starting to pull in. The firm sees little upside to Q4 estimates and likely reductions in Q1. Price target lowered to $10 from $11.
05:44 EDTHUBGHub Group initiated with an Equal Weight at Barclays
Subscribe for More Information
September 9, 2014
16:44 EDTHUBGHub Group sees intermodal volume flat or down slightly for remainder of year
Subscribe for More Information
16:39 EDTHUBGHub estimates that settlement amount for drivers case is approximately $9.5M
Hub Group disclosed in a regulatory filing that "as previously reported in a Form 10-K and 10-Q, a complaint was filed in the U.S. District Court for the Eastern District of California by Salvador Robles against our subsidiary, Comtrak Logistics, now known as Hub Group Trucking. The complaint seeks class certification on behalf of a class comprised of present and former California-based truck drivers for Hub Group Trucking who were classified as independent contractors, from January 2009 to the present. The complaint alleges Hub Group Trucking has misclassified such truck drivers as independent contractors and that such drivers were employees. A second complaint alleging substantially similar claims was filed in the Superior Court of the State of California for the County of San Bernardino on July 24, but the company has not been served with a copy of that complaint. The company believes that the independent contractor truck drivers were properly classified as independent contractors at all times. Nevertheless, because lawsuits are expensive, time-consuming and could interrupt our business operations, we have decided to make settlement offers to individual drivers with respect to the claims alleged in the lawsuits, without admitting liability. The company estimates that the total settlement amount, if all drivers accept the offers, is approximately $9.5M. To date, a substantial number of the independent contractors have decided to accept the settlement offer. We are also changing our business model in California from independent contractor truck drivers to employee drivers. In the Los Angeles and Stockton markets, the cost of the employee driver model will initially be higher than the independent contractor model and will fluctuate depending on the cost of various factors, including claims, repairs and fuel. We estimate that the impact of the change in the model for the remainder of the year would be between two and four cents per share. In addition, we expect a total of approximately $1M (or about two cents per share) of one time costs in the last half of 2014 for legal, travel and communication costs related to the settlements and model change implementation."
06:51 EDTARMHARM Holdings management to meet with JMP Securities
Meeting to be held in Los Angeles on September 12 hosted by JMP Securities.
06:20 EDTNKEForrester: Apple could sell 10M iWatches this year, FT reports
Subscribe for More Information
September 8, 2014
10:06 EDTFEYEOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:12 EDTFEYEOn The Fly: Pre-market Movers
Subscribe for More Information
08:02 EDTCACICACI awarded prime position on $44M contract to support NAVSEA's PEO LCS
Subscribe for More Information
07:15 EDTLLYIBC Life Sciences to hold a conference
10th Annual Cell Line Development & Engineering Conference to be held in Berkeley, California on September 8-10.
07:01 EDTLLYIgnyta names Robert Wild as Chief Scientific Officer
Subscribe for More Information
06:31 EDTFEYEFireEye upgraded to Buy from Neutral at UBS
Subscribe for More Information
September 5, 2014
06:27 EDTYELPCourt rules Yelp has no obligation to show positive reviews, WSJ reports
Subscribe for More Information
September 4, 2014
19:53 EDTALGTAllegiant Travel reports August revenue passenger miles up 14.5% vs prior year
The company reported August passengers up 16.7% vs prior year, along with available seat miles up 16.5%, departures up 18.1%, and average stage length down 1.4%. Estimates for average fuel cost per gallon for August was $3.12.
09:02 EDTMNKMallinckrodt announces MNK-155 Phase 3 efficacy trial met primary endpoint
Mallinckrodt reported that a Phase 3 efficacy trial of investigational MNK-155 met the study’s primary endpoint of improved pain scores vs. placebo over the first 48 hours following bunionectomy. This difference in pain scores was statistically significant in favor of MNK-155. The data is being presented at PAINWeek 2014 on September 2-6. In addition to the Phase 3 study, Mallinckrodt will present data at PAINWeek from several other MNK-155 trials, including the pharmacokinetics, safety and subjective effects of abuse-related characteristics.
08:11 EDTLLYEli Lilly's insulin peglispro for diabetes shows positive Phase III results
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use